NCT06941142View on ClinicalTrials.gov

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

382

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

June 30, 2028

Conditions
Advanced Breast Cancer
Interventions
DRUG

Sirolimus (albumin - bound)

Dose escalation, intravenous infusion

DRUG

Palbociclib tablet

The dosage is 125 mg, orally once a day. Taken continuously for three weeks followed by a one - week break, with a treatment cycle of four weeks

DRUG

Fulvestrant injection

The dosage is 500 mg, intramuscular injection. It is given on the 1st and 15th days of the first cycle, with a treatment cycle of four weeks. After that, it is administered once every four weeks.

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY